MacroGenics Inc. (MGNX) Plunges 5.09%

MacroGenics Inc. (MGNX) Plunges 5.09%

MacroGenics Inc. (MGNX) had a rough trading day for Tuesday December 10 as shares tumbled 5.09%, or a loss of $-0.5 per share, to close at $9.33. After opening the day at $9.85, shares of MacroGenics Inc. traded as high as $9.90 and as low as $9.07. Volume was 1.18 million shares over 5,865 trades, against an average daily volume of n/a shares and a total float of 48.92 million.

As a result of the decline, MacroGenics Inc. now has a market cap of $456.4 million. In the last year, shares of MacroGenics Inc. have traded between a range of $32.32 and $7.43, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company’s strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company’s intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

MacroGenics Inc. is based out of Rockville, MD and has some 364 employees. Its CEO is Scott Koenig.

MacroGenics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!